Logotype for Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals (CYCC) investor relations material

Cyclacel Pharmaceuticals Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cyclacel Pharmaceuticals Inc
Q2 2025 earnings summary13 Aug, 2025

Executive summary

  • Deconsolidation and liquidation of UK subsidiary Cyclacel Limited resulted in a $5.0 million gain and strategic refocus on the plogosertib program.

  • Entered into a share exchange agreement to acquire FITTERS Sdn. Bhd., pending shareholder approval, with a special meeting set for September 4, 2025.

  • Implemented two reverse stock splits in May and July 2025 to meet Nasdaq requirements, significantly reducing outstanding shares.

  • Raised $3 million through a private placement of Series F Convertible Preferred Stock in June 2025.

  • Incorporated a new Malaysian subsidiary, BIGM Capital, which has not yet commenced operations.

Financial highlights

  • Cash and cash equivalents were $4.3 million as of June 30, 2025, up from $3.1 million at year-end 2024.

  • Net loss for the six months ended June 30, 2025 was $1.4 million, a significant improvement from $6.2 million for the same period in 2024.

  • Net loss for Q2 2025 was $1.3 million, compared to $3.3 million for Q2 2024.

  • No revenue recognized in the first half of 2025, compared to $33,000 in the same period last year.

  • Operating expenses decreased to $1.3 million for the quarter, down from $3.6 million year-over-year.

Outlook and guidance

  • Cash on hand expected to fund operations into Q4 2025; substantial doubt remains about ability to continue as a going concern without additional financing.

  • Anticipates increased revenues and expenditures if the acquisition of Fitters Sdn. Bhd. is completed in Q4 2025.

  • Research and development expenses expected to decrease for the remainder of 2025 as focus narrows to plogosertib.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Cyclacel Pharmaceuticals earnings date

Logotype for Cyclacel Pharmaceuticals Inc
Q3 202511 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Cyclacel Pharmaceuticals earnings date

Logotype for Cyclacel Pharmaceuticals Inc
Q3 202511 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The company's research and development efforts target the regulation of the cell cycle, aiming to treat cancers and other serious diseases that result from abnormal cell division. Cyclacel's pipeline includes small-molecule drugs designed to inhibit specific enzymes and proteins involved in cancer cell growth and survival. The company's therapeutic candidates are being developed for a range of oncology applications, with the goal of addressing unmet medical needs in cancer treatment. The company is headquartered in Berkeley Heights, New Jersey, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage